Costs of EU anti-falsification technologies threaten access to low priced generic medicines
26/04/2012 - Producers of generic medicines are raising concerns on the huge cost implications of possible new anti-falsification technologies that will be required as a result of Directive 2011/62/EU on falsified medicines.
EGA president calls for global development of biosimilars to achieve their potential
19/04/2012 - “The need for a framework which allows global biosimilars development is now crucial” announced EGA President Gudbjorg Edda Eggertsdottir in her opening address at the 10th EGA International Symposium on Biosimilars today in London. Taking the critical example of the huge increase in diabetes in the coming years, EGA’s President highlighted that the access to affordable biosimilar insulin will be key for treating millions of patients worldwide. “Biosimilars will also promote significant cost savings that help to safeguard the sustainability of European and indeed global healthcare systems while ensuring access to high standard treatment for patients” Ms Eggertsdottir said.
Commission proposals to revise transparency directive address key recommendations of the pharmaceutical sector inquiry
01/03/2012 - “The revision of the Transparency Directive must be viewed as an opportunity to implement certain key recommendations of the Pharmaceutical Sector Inquiry* which identified reasons why generic medicines are blocked or delayed from entering the market. We therefore welcome the European Commission’s decision to take on board measures that will help guarantee that generic medicines will continue to be made available to as many patients as quickly as possible at affordable prices” said Greg Perry, EGA Director.
European Commission and Mario Monti’s government seek to increase patient access to generic medicines
27/1/2012 - The European Generic medicines Association (EGA) together with the Italian association for generic medicines (ASSOGENERICI) welcome the European Commission’s formal call yesterday on Italy to comply with EU rules on the marketing authorisation of generic medicines.
